Osteoporosis

New data suggests that zoledronic acid increases bone density

Published in Women's Health Weekly, April 4th, 2002

A new study published in The New England Journal of Medicine demonstrates that the Novartis drug zoledronic acid, an intravenous bisphosphonate, significantly increases bone density in women with postmenopausal osteoporosis.

This is the first time that a bisphosphonate, given at intervals of up to 1 year between doses, has produced sustained suppression of bone turnover and an increase in bone mineral density in the spine and hip as great as that seen with oral daily or weekly dosing of other bisphosphonates.

"Oral bisphosphonates, although effective in treating osteoporosis, have complicated dosing requirements that can lead to compliance...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-04-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry